On August 27, the Aging in Motion (AIM) Coalition presented the first in a series of biannual webinars on the future of research, therapeutic development, and treatment of sarcopenia. This one-hour webinar highlighted best practices from a successful public-private partnership qualifying Patient-Reported Outcome (PRO) measures in multiple therapeutic areas; explored diverse stakeholder perspectives on the role of PRO measures in supporting the regulatory assessment of sarcopenia treatments; and featured the relevance of PRO measures in capturing changes in mobility and improvements in quality of life for sarcopenic patients.
It featured the following speakers:
Ronenn Roubenoff, M.D., MHS
Global Translational Medicine Head, Musculoskeletal Disease
Global Translational Medicine Head ad interim, Cell Therapies
Novartis Institutes for Biomedical Research
Stephen Joel Coons, Ph.D.
Executive Director, PRO Consortium
The Critical Path Institute
Wen-Hung Chen, Ph.D.
Reviewer, Clinical Outcome Assessment Staff
Office of New Drugs, Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Cynthia Bens (Moderator)
Vice President of Public Policy, Alliance for Aging Research
Executive Director, Aging In Motion